期刊文献+

局部应用IL-12对小鼠S180实体瘤的抗瘤效应及机制初探 被引量:1

Antitumor Effects on Mice with S180 Solid Tumor Treated by Topical IL-12 and Its Mechanism
下载PDF
导出
摘要 目的研究白细胞介素-12(Interleukin 12,IL-12)对小鼠S180实体瘤的抗肿瘤作用并初步探讨其机制.方法将小鼠左后肢皮下接种S180细胞荷瘤后的BaLB/c小鼠随机分为生理盐水组和IL-12组,分别给予生理盐水和IL-12.接种第28天,眼球取血,流式细胞仪分析外周血T细胞亚群的变化;解剖取瘤称重,计算瘤指数和抑瘤率,组织切片进行形态学观察.结果在接种瘤细胞第14天时,IL-12组、生理盐水组的肿瘤大小分别达到(7.56±0.09)mm、(8.52±0.46)mm,到第27天时,IL-12组的肿瘤大小为(5.12±1.56)mm,明显小于生理盐水组(15.34±3.18)mm(P<0.01).IL-12组的抑瘤率为(31.85±7.24)%,IL-12组的小鼠瘤指数为(5.51±1.35),与生理盐水组(7.67±0.67)相比差异具有显著性(P<0.01).IL-12组的小鼠血液中CD3+T、CD4+T、CD8+T细胞均高于生理盐水组.生理盐水组小鼠肿瘤细胞无明显坏死,并可见有丝分裂象,IL-12组的小鼠肿瘤组织有明显坏死,核固缩、细胞碎片多,但在瘤细胞之间很少见到淋巴细胞及巨噬细胞.结论 IL-12具有明显的抗肿瘤作用,初步显示涉及改变细胞亚群和诱导细胞凋亡的机制. Objectives To study the antitumor function and mechanism of IL-12 in treating S180 solid tumors in mice.Methods The tumor-bearing mice which were inoculated with S180 cells(1×107/ml) subcutaneously in the left hind limb were divided into two groups:NS control group and IL-12 treatment group.And NS,IL-12 were respectively given to the mice of two groups.The ocular blood was removed from the mouse of each group on the 28th day to analyze.Then CD3+T,CD4+T,CD8+T and the ratio of CD4/CD8 of peripheral blood was analyzed with FCM,and tumor tissue was dissected completely for weighting and calculating the inhibition rate and index.The regular diet and physical conditions of the remaining mice were observed,and their tumor size was measured.Results On the 14th day,tumor size of NS control group,IL-12 group respectively got to(8.52±0.46) mm,(7.56±0.09) mm.Then it began to reduce in the IL-12 group.On the 27th day,tumor size was(5.12±1.56) mm and significantly less than that of NS control group(15.34±3.18) mm(P0.01).The tumor inhibition rate of IL-12 group was(31.85±7.24)%,significantly higher than that of NS group(P0.01).Tumor index of NS control group was 7.67 ± 0.67 and tumor index of IL-12 group was 5.51±1.35,which was significantly lower than that of NS control group(P0.01).CD3+T,CD4+T,CD8+T cells in mice blood of IL-12 group were all higher than that of NS control group.Tumor cells of mice in NS group had no significant necrosis,and Mitosis was observed.Tumor tissue of mice in IL-12 group had significant necrosis with most karyopyknosis and cell debris,but lymphocytes and macrophages between tumor cells rarely seen. Conclusions IL-12 has apparente effects in anti-tumor immune response.And it demonstrats that IL-12 relates to the mechanism of changing cell subpopulation and leading apotosis.
出处 《河北北方学院学报(自然科学版)》 2011年第5期62-66,共5页 Journal of Hebei North University:Natural Science Edition
关键词 肿瘤 免疫治疗 IL-12 细胞免疫 S180瘤细胞 tumor immunotherapy interleukin 12 cellular immunity mouse sarcoma S180 cells
  • 相关文献

参考文献9

  • 1Kilinc MO, Aulakh KS, Nair RE, et al. Reversing tumor immune suppression with intratumoral II. 12.. Activation of tumor-associated T effector/memory cells, induction of T suppressor apotosis, and infiltration of CD8+ T effedctors [J]J Immunol, 2006, 177 (10): 6962-6973.
  • 2张建华,赵德矿,王青青,沈芬平,翁跃颂.IL-12基因联合CD40L基因治疗小鼠黑色素瘤的实验研究[J].中国免疫学杂志,2007,23(5):426-429. 被引量:1
  • 3Portielje JE, Gratama JW, van Ojik H H, et al. IL-12: a promising adjuvant for cancer vaccination ~J]. Cancer Immu- nollmmun, 2003, 52 (03): 133-44.
  • 4Colombo MP, Trinchieri G. Interleukin-12 in anti-tumor immunity and immunotherapy [J]. Cytokine Growth Factor Rev. 2002, 13 (02).. 155-68.
  • 5Kanagawa N, Gao JQ, Motomura Y, et al. Anti-tumor mechanism of intratumoral injection with IL-12-expressing ade- noviral vector against IL-12-unresponsive tumor [J]. Biochem Biophys Res Commun, 2008, 372 (04): 821-825.
  • 6Wang S, Zheng Z, Weng Y, et al. Angiogenesis and anti-angiogenesis activity of Chinese medical herbal extracts EJ]. LifeSci, 2004, 74 (20): 2467-2478.
  • 7Waldmann TA. Effective cancer therapy through immunomodulation [J]. Annu Rev Med, 2006, 57:65-81.
  • 8Watkins SK, Egilrnez NK, Suttles J, et al. IL-12 rapidly alters the functional profile of tumor-associated and tumor-in- filtrating macrophages in vitro and in vivo [J]. J Imrnunol, 2007, 178 (03) .. 1357-62.
  • 9Cao X, Leonard K, Collins LI, et al. Interleukin 12 stimulates IFN-gamma-mediated inhibition of tumor-induced regu- latory T-cell proliferation and enhances tumor clearance [J] Cancer Res, 2009, 69 (22) .. 8700-8709.

二级参考文献13

  • 1Wierda W G,Cantwell M J,Woods S J et al.CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia[J].Blood,2000; 96(9):2917-2924.
  • 2Kikuchi T,Crystal R G.Anti-tumor immunity induced by in vivo adenovirus vector-mediated expression of CD40 ligand in tumor cells[J].Hum Gene Ther,1999; 10(8):1375-1387.
  • 3Sun Y,Peng D,Lecanda J et al.In vivo gene transfer of CD40 ligand into colon cancer cells induces local production of cytokines and chemokines,tumor eradication and protective antitumor immunity[J].Gene Ther,2000; 7(17):1467-1476.
  • 4Lamont A G,Adorini L.IL-12:a key cytokine in immune regulation[J].Immunol Today,1996; 17:214-217.
  • 5Marshall E.Cancer trial of interleukin-12 halted[J].Science,1995; 268:1555.
  • 6Caruso M,Pham-Nguyen K,Kwong Y L et al.Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma[J].Proc Natl Acad Sci USA,1996; 93(21):11302-11306.
  • 7Gambotto A,Tuting T,McVey D L et al.Induction of antitumor immunity by direct intratumoral injection of a recombinant adenovirus vector expressing interleukin-12[J].Cancer Gene Ther,1999; 6 (1):45-53.
  • 8Liu Y,Ehtesham M,Samoto K et al.In situ adenoviral interleukin 12 gene transfer confers potent and long-lasting cytotoxic immunity in glioma[J].Cancer Gene Ther,2002; 9(1):9-15.
  • 9Melero I,Mazzolini G,Narvaiza I et al.IL-12 gene therapy for cancer:in synergy with other immunotherapies[J].Trends Immunol,2001; 22(3):113-115.
  • 10Ulett G C,Ketheesan N,Hirst R G.Cytokine gene expression in innately susceptible BALB/c mice and relatively resistant C57BL/6 mice during infection with virulent Burkholderia pseudomallei[J].Infect Immun,2000; 68 (4):2034-2042.

同被引文献12

  • 1段迎春,胡平.宫颈癌的治疗进展[J].国外医学(妇产科学分册),2007,34(2):137-139. 被引量:31
  • 2Gajewski TF, Meng Y,Harlin H, et al. Immune suppression inthe tumor microenvironment[ J]. Immunother, 2006, 29(3) : 233-240.
  • 3Wolf SF, Temple PA, Kobayshi M, et al. Cloning of cDNA fornatural killer cell stimulatory factor,a heterodimeric cytokine with multi-ple biologic effects on human lymphocytes [ J ]. J Immunol, 1991,146 :3074-3081.
  • 4Aggarwal S, Ghilard N, Xie H, et al. Interleukin-23 promotes adistinct CD4 + T cell activation state characterized by the production of in-terleukin-17 [J]. J Biol Chem, 2003, 278(3) :1910-1917.
  • 5Numasaki M,Watanabe M, Suzuki T,et al. IL-17 enhances the netangiogenic activity and in vivo growth of human non-small cell lung cancerin SCID mice through promoting CXCR-2 -dependent angiogenesis [ J ]. JImmunol,2005,175(9) :6177.
  • 6Wang L, Yi T, Kortylewski M, et al. IL-17 can promote tumorgrowth through an IL-6-State signaling pathway[ J]. J Exp Med,2009,206(7):1457-1464.
  • 7Honorati MC,Cattini I,Faechini A. Possible prognostic role of IL-17R in osteosarcoma[ J]. J Cancer Res Clin Oncol,2007,133(12) : 1017-1021.
  • 8Gey A,Kumari P,Sambandam A,et al. Identification and charac-terisation of a group of cervical carcinoma patients with profound downreg-ulation of intratumoral Type 1 (IFN-7) and Type 2(IL-4) cytokine mRNAexpression [ J]. European J Cancer,2003,39(5) :595-603.
  • 9孙晋瑞,张彦娜,冯淑瑜,严鸣,程海燕,孙学明.Ⅰb~Ⅱa期子宫颈癌预后分析[J].中华妇产科杂志,2010,45(3):224-226. 被引量:7
  • 10孙伟,张逊,韩兴鹏.肺癌患者IFN-γ和TNF-α免疫因子检测及其临床意义[J].细胞与分子免疫学杂志,2010,26(9):891-892. 被引量:5

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部